PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
NCT ID: NCT07023094
Last Updated: 2025-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
60 participants
INTERVENTIONAL
2025-06-16
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PENG Block vs. ESP Block for Pediatric Hip Surgery
NCT06087549
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
NCT07180979
PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery
NCT07288983
Erector Spinae vs. PENG Block for Total Hip Arthroplasty
NCT06083428
Quadratus Lumborum vs Erector Spinae Supplementary Blocks With Lumbar Plexus Blocks for Hip PAO
NCT04481451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This randomized controlled trial aims to compare the analgesic effectiveness of two regional anesthetic approaches:
\- The pericapsular nerve group (PENG) block is combined with the lateral fetal cutaneous nerve block (LFCB), targeting hip joint innervation directly and providing comprehensive sensory coverage.
Lumbar and sacral erector spinae plane blocks (L-ESPB and S-ESPB) employ fascial plane techniques to deliver analgesia by diffusing local anesthetic around nerves innervating the hip region.
This trial aims to establish the optimal regional anesthesia technique and determine the clinical benefits of using dexamethasone and dexmedetomidine as adjuvants. The results will guide clinicians toward evidence-based analgesic protocols in pediatric orthopedic hip surgery, potentially reducing opioid-related complications and improving patient recovery outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PENG + LFCB
U-S guided PENG block - 0.4ml/kg 0.2% ropivacaine
\+ U-S guided LFCB - 0.1ml/kg 0.2% ropivacaine
Ropivacaine 0.2% for PENG Block
U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine
Ropivacaine 0.2% for LFCB
LFCB (0.1 mL/kg) with 0.2% ropivacaine
L-ESPB + S-ESPB
U-S guided L-ESPB - 0.25ml/kg 0.2% ropivacaine
\+ U-S guided S-ESPB - 0.25ml/kg 0.2% ropivacaine
Ropivacaine 0.2% for L-ESPB
Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine
Ropivacaine 0.2% for S-ESPB
Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivacaine 0.2% for PENG Block
U-S guided PENG (0.4 mL/kg) with 0.2% ropivacaine
Ropivacaine 0.2% for LFCB
LFCB (0.1 mL/kg) with 0.2% ropivacaine
Ropivacaine 0.2% for L-ESPB
Lumbar ESPB (0.25ml/kg) with 0.2% ropivacaine
Ropivacaine 0.2% for S-ESPB
Sacral ESPB (0.25ml/kg) with 0.2% ropivacaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled for elective orthopedic hip surgery, including: Osteotomies and Hip reconstruction surgeries
* ASA (American Society of Anesthesiologists) physical status classification: I-III.
* Written informed consent obtained from the patient's legal guardian(s).
Exclusion Criteria
* Presence of infection or inflammation at the intended injection site(s) of regional anesthesia.
* Coagulopathy or bleeding disorders (including patients on anticoagulant therapy) that contraindicate nerve blocks.
* Neurological disorders or peripheral neuropathies that could influence sensory or motor assessment of the lower limbs.
* Cognitive impairment or behavioral disorders significantly affecting pain assessment accuracy or cooperation.
* History of chronic opioid use or known substance abuse.
* Severe systemic disease or condition compromising patient safety or interfering with study protocol adherence.
2 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poznan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malgorzata Reysner, M.D. Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Poznan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poznan University of Medical Sciences
Poznan, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6/2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.